StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC - Get Free Report) in a report issued on Saturday. The brokerage set a "sell" rating on the biotechnology company's stock.
Cyclacel Pharmaceuticals Stock Performance
Cyclacel Pharmaceuticals stock traded down $0.84 during trading on Friday, reaching $2.75. The company had a trading volume of 325,659 shares, compared to its average volume of 101,960. The firm has a market capitalization of $570.17 million, a PE ratio of -0.29 and a beta of 0.52. The firm's 50-day simple moving average is $4.28 and its 200 day simple moving average is $5.50. Cyclacel Pharmaceuticals has a 1-year low of $2.70 and a 1-year high of $49.34.
Cyclacel Pharmaceuticals (NASDAQ:CYCC - Get Free Report) last released its quarterly earnings results on Wednesday, April 2nd. The biotechnology company reported ($5.28) earnings per share for the quarter, missing the consensus estimate of ($4.64) by ($0.64). Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 18,150.00%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million.
Insider Transactions at Cyclacel Pharmaceuticals
In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 12,164,301 shares of the firm's stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $0.48, for a total value of $5,838,864.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 68.00% of the company's stock.
Cyclacel Pharmaceuticals Company Profile
(
Get Free Report)
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
Further Reading
Before you consider Cyclacel Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cyclacel Pharmaceuticals wasn't on the list.
While Cyclacel Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
